Considering that P-glycoprotein transporter (P-gp) is also associated with urate transport in intestine [31] and dioscin has been reported to inhibit P-gp in cancer cells [34–37], dioscin may be a promising candidate for developing antihyperuricemic therapies. Here, PGP is linked to cancer.